Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

290.10
-12.5900-4.16%
Post-market: 290.100.00000.00%18:58 EDT
Volume:398.73K
Turnover:117.18M
Market Cap:8.08B
PE:-21.53
High:305.94
Open:302.68
Low:288.59
Close:302.69
52wk High:356.00
52wk Low:26.70
Shares:27.85M
Float Shares:25.78M
Volume Ratio:0.69
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.4758
EPS(LYR):-13.4758
ROE:-45.83%
ROA:-28.69%
PB:9.20
PE(LYR):-21.53

Loading ...

Praxis Precision Medicine Q4 EPS $(3.50) Misses $(3.08) Estimate

Benzinga
·
Feb 19

Praxis reports FY 2025 R&D expenses up 1.75x to USD 267.1 million

Reuters
·
Feb 19

BRIEF-Praxis Precision Q4 EPS USD -3.5

Reuters
·
Feb 19

Press Release: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Dow Jones
·
Feb 19

Earning Preview: Praxis Precision Medicines, Inc. Q4 revenue is expected to decrease by 88.06%, and institutional views are bullish

Earnings Agent
·
Feb 12

Praxis Precision Medicines Updates Non-Employee Director Compensation Policy

Reuters
·
Feb 11

Praxis Precision Med Is Maintained at Buy by Guggenheim

Dow Jones
·
Feb 10

Praxis Precision Medicines Inc. published an update to their financial calendar

Reuters
·
Feb 10

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 10

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Feb 09

Praxis Precision Medicines Grants Restricted Stock Units to New Employees Under 2024 Inducement Plan

Reuters
·
Feb 05

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 05

Praxis Precision Med Is Maintained at Buy by Needham

Dow Jones
·
Feb 04

Needham Upside Case: Strong Ulixacaltamide Outlook and 2026 Catalyst Stack Drive Praxis Buy Thesis

TIPRANKS
·
Feb 04

Praxis Precision Med Initiated at Equal-Weight by Wells Fargo

Dow Jones
·
Feb 02

Wells Fargo Initiates Coverage on Praxis Precision Medicines With Equal Weight Rating, $282 Price Target

MT Newswires Live
·
Feb 02

Praxis Precision Med Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 31

Praxis Precision Medicines Inc : TD Cowen Raises Target Price to $554 From $353

THOMSON REUTERS
·
Jan 29

TD Cowen Remains a Buy on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jan 29

Praxis Precision Med Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 28